INTRODUCTION: Most epidermal growth factor receptor (EGFR) mutant non-small cell lung cancers (NSCLCs) are sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, but many EGFR wild type NSCLCs are resistant to TKIs. In this study, we examined the effects of the histone deacetylase inhibitor, romidepsin, in combination with erlotinib, in NSCLC cell lines and xenografts. METHODS: For in vitro studies, nine NSCLC cell lines with varying mutation status and histology were treated with erlotinib and romidepsin alone or in combination. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assays were performed to determine the concentration that inhibits 50% (IC50) value of each drug or the combination. For in vivo studies, NCI-H1299 xenografts were inoculated subcutaneously into athymic nude mice. Romidepsin and/or erlotinib were injected intraperitoneally after tumors developed and tumor sizes were measured. RESULTS: We found that romidepsin increased the sensitivity of erlotinib synergistically in all nine NSCLC cell lines including EGFR and KRAS wild type cell lines, KRAS mutant cell lines, and TKI resistant EGFR mutant cell lines. This effect was partially due to enhanced apoptosis. Furthermore, cotreatment of erlotinib and romidepsin inhibited NCI-H1299 xenograft growth in athymic nude mice. CONCLUSIONS: These observations support a role for the combination of a histone deacetylase inhibitor and a TKI in the treatment of NSCLCs.
INTRODUCTION: Most epidermal growth factor receptor (EGFR) mutant non-small cell lung cancers (NSCLCs) are sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, but many EGFR wild type NSCLCs are resistant to TKIs. In this study, we examined the effects of the histone deacetylase inhibitor, romidepsin, in combination with erlotinib, in NSCLC cell lines and xenografts. METHODS: For in vitro studies, nine NSCLC cell lines with varying mutation status and histology were treated with erlotinib and romidepsin alone or in combination. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assays were performed to determine the concentration that inhibits 50% (IC50) value of each drug or the combination. For in vivo studies, NCI-H1299 xenografts were inoculated subcutaneously into athymic nude mice. Romidepsin and/or erlotinib were injected intraperitoneally after tumors developed and tumor sizes were measured. RESULTS: We found that romidepsin increased the sensitivity of erlotinib synergistically in all nine NSCLC cell lines including EGFR and KRAS wild type cell lines, KRAS mutant cell lines, and TKI resistant EGFR mutant cell lines. This effect was partially due to enhanced apoptosis. Furthermore, cotreatment of erlotinib and romidepsin inhibited NCI-H1299 xenograft growth in athymic nude mice. CONCLUSIONS: These observations support a role for the combination of a histone deacetylase inhibitor and a TKI in the treatment of NSCLCs.
Authors: M Hidalgo; L L Siu; J Nemunaitis; J Rizzo; L A Hammond; C Takimoto; S G Eckhardt; A Tolcher; C D Britten; L Denis; K Ferrante; D D Von Hoff; S Silberman; E K Rowinsky Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 44.544
Authors: Xiaodan Yu; Z Sheng Guo; Monica G Marcu; Len Neckers; Dao M Nguyen; G Aaron Chen; David S Schrump Journal: J Natl Cancer Inst Date: 2002-04-03 Impact factor: 13.506
Authors: Hisayuki Shigematsu; Li Lin; Takao Takahashi; Masaharu Nomura; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; Ziding Feng; Jack A Roth; Joachim Herz; John D Minna; Adi F Gazdar Journal: J Natl Cancer Inst Date: 2005-03-02 Impact factor: 13.506
Authors: Ailan Guo; Judit Villén; Jon Kornhauser; Kimberly A Lee; Matthew P Stokes; Klarisa Rikova; Anthony Possemato; Julie Nardone; Gregory Innocenti; Randall Wetzel; Yi Wang; Joan MacNeill; Jeffrey Mitchell; Steven P Gygi; John Rush; Roberto D Polakiewicz; Michael J Comb Journal: Proc Natl Acad Sci U S A Date: 2008-01-07 Impact factor: 11.205
Authors: David E Gerber; David A Boothman; Farjana J Fattah; Ying Dong; Hong Zhu; Rachel A Skelton; Laurin L Priddy; Peggy Vo; Jonathan E Dowell; Venetia Sarode; Richard Leff; Claudia Meek; Yang Xie; Joan H Schiller Journal: Lung Cancer Date: 2015-10-09 Impact factor: 5.705
Authors: Missak Haigentz; Mimi Kim; Catherine Sarta; Juan Lin; Roger S Keresztes; Bruce Culliney; Anu G Gaba; Richard V Smith; Geoffrey I Shapiro; Lucian R Chirieac; John M Mariadason; Thomas J Belbin; John M Greally; John J Wright; Robert I Haddad Journal: Oral Oncol Date: 2012-06-28 Impact factor: 5.337
Authors: Kenichi Suda; Paul A Bunn; Christopher J Rivard; Tetsuya Mitsudomi; Fred R Hirsch Journal: J Thorac Oncol Date: 2016-09-15 Impact factor: 15.609
Authors: Melissa J LaBonte; Peter M Wilson; William Fazzone; Susan Groshen; Heinz-Josef Lenz; Robert D Ladner Journal: BMC Med Genomics Date: 2009-11-30 Impact factor: 3.063